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A key feature in Huntington disease (HD) is the
accumulation of mutant Huntingtin (HTT) protein,
which may be regulated by posttranslational modifi-
cations. Here, we define the primary sites of
SUMO modification in the amino-terminal domain
of HTT, show modification downstream of this
domain, and demonstrate that HTT is modified by
the stress-inducible SUMO-2. A systematic study
of E3 SUMO ligases demonstrates that PIAS1 is
an E3 SUMO ligase for both HTT SUMO-1 and
SUMO-2 modification and that reduction of dPIAS
in a mutant HTT Drosophila model is protective.
SUMO-2 modification regulates accumulation of
insoluble HTT in HeLa cells in a manner that mimics
proteasome inhibition and can be modulated by
overexpression and acute knockdown of PIAS1.
Finally, the accumulation of SUMO-2-modified pro-
teins in the insoluble fraction of HD postmortem
striata implicates SUMO-2 modification in the age-
related pathogenic accumulation of mutant HTT
and other cellular proteins that occurs during HD
progression.362 Cell Reports 4, 362–375, July 25, 2013 ª2013 The AuthorsINTRODUCTION
Huntington disease (HD) is caused by the expansion of a
CAG repeat within the HD gene and the corresponding poly-
glutamine track within the Huntingtin (HTT) protein (MacDonald
et al., 1993). Symptoms include movement abnormalities,
psychiatric symptoms, and cognitive deficits with accompa-
nying degeneration of medium spiny neurons in striatum and
loss of cortical volume (Ross and Tabrizi, 2011). Posttransla-
tional modifications modulate protein function, and HTT is
subject to multiple functionally relevant modifications including
SUMOylation, ubiquitination, acetylation, palmitoylation, and
phosphorylation (for review, see Ehrnhoefer et al., 2011; Pen-
nuto et al., 2009). We previously demonstrated that a fragment
of mutant HTT is modified by Small Ubiquitin-like MOdifier 1
(SUMO-1), and genetic reduction of SUMO in Drosophila-
expressing mutant HTT exon 1 is protective (Steffan et al.,
2004). SUMO-1 modification of mutant HTT in cells was also
associated with increased toxicity and decreased aggrega-
tion by the striatal enriched small guanine nucleotide-binding
protein Rhes (Subramaniam et al., 2009). SUMO modification
is also implicated in Alzheimer’s disease (AD), Parkinson’s
disease (PD), and amyotrophic lateral sclerosis (ALS), as
well as other CAG repeat diseases (SBMA, DRPLA, SCA1,
and SCA7) (for review, see Krumova and Weishaupt, 2013; La
Spada and Taylor, 2010; Wilkinson et al., 2010). Although this
AB
Figure 1. K6 and K9 Are Primary Sites for
HTTex1p In Vitro SUMOylation
(A) Schematic illustration of the SUMOylation
pathway. SUMO is expressed as a precursor
protein (SUMO-X) that is processed by SUMO-
specific proteases (SENPs) to expose a C-terminal
diglycine motif (-GG). Enzymatic reactions are
similar to ubiquitination and include activation
by the SUMO E1-activating enzyme (SAE1/UBA2),
to the SUMO E2-conjugating enzyme (Ubc9),
and transfer of SUMO to target lysines with or
without the assistance of the SUMO E3-ligating
enzymes.
(B) Time course of SUMO-1 modification of His-
tagged HTTex1p (25Q)-purified proteins (WT, K6R,
K9R, K6,9R, K6,9,15R, and S13,16D) was per-
formed in vitro. SUMOylation was visualized using
anti-His antibody. WT HTTex1p is SUMOylated
within 16 min, K6R or K9R mutations delay
SUMOylation, and combined mutations (K6,9R or
K6,9,15R) greatly reduce SUMOylation. Mutations
that mimic phosphorylation (S13,16D) alter
kinetics of SUMO-1 modification with SUMO
modification observed beginning by 4 min.
See also Figure S1.modification is linked to pathogenesis, the precise mechanisms
involved have not yet been elucidated.
SUMO modification is the covalent attachment of SUMO to
specific lysine residues within a target protein and regulates
key processes involved in normal cellular function, including
subcellular localization, protein stability, transcriptional regula-
tion, and interaction properties of SUMO-modified proteins
with their cellular targets (Cuben˜as-Potts and Matunis, 2013;
Gareau and Lima, 2010). Although highly transient, the
effects of this modification are long lasting (Johnson, 2004).
Four different forms, SUMO-1–SUMO-4, exist in mammals.
SUMO-2 and SUMO-3 are nearly identical (97% identity) and
often referred to as one protein (SUMO-2/SUMO-3) (Gareau
and Lima, 2010; Johnson, 2004), and SUMO-4 is found only in
a precursor form (Bohren et al., 2004). The SUMOylation
pathway involves a cascade of enzymes, similar to ubiquitina-
tion, with a single E1-activating enzyme (SAE1/UBA2), a single
E2-conjugating enzyme (UBC9), multiple E3-ligating enzymes
(Protein Inhibitors of Activated STAT [PIAS], PC2, MMS21, and
RanBP2), which provide substrate specificity, and multiple pro-
teases (SENPs) that both cleave the SUMO moiety from target
proteins and process SUMO itself (Figure 1A). Given that
SUMOylation is implicated in HD and other neurodegenerative
diseases, identification of the E3s responsible for HTT modifica-
tion may provide insight into mechanisms underlying HD and
provide novel therapeutic targets.
Here, we systematically evaluated the enzymatic machinery
involved in HTT SUMO modification and report for the first time
that HTT is modified by SUMO-2 and that PIAS1 functions as a
HTT SUMO E3 ligase. This modification may serve more than
one function because longer HTT polypeptides, both wild-type
(WT) and mutant, are SUMO modified downstream of exon 1.
SUMO-2 overexpression causes mutant HTT to accumulate incells. In HD postmortem striatum, SUMO-2-modified proteins
accumulate in the insoluble fraction, suggesting that this modifi-
cation is relevant in vivo to HD. Further validating the potential
in vivo relevance for SUMO modification pathways in HD,
genetic reduction of dPIAS in Drosophila expressing expanded
repeat HTT is neuroprotective. Taken together, these results
provide a rationale for targeting SUMO-2 and PIAS1 as novel
therapeutic targets for HD.
RESULTS
HTTex1p Lys 6 and Lys 9 Are the Primary Sites of SUMO
Modification
We previously showed that truncated HTT (Httex1p) is SUMO-1
modified in cells and that Lys 6 (K6) and Lys 9 (K9) may represent
primary sites for modification based on the absence of SUMO
modification upon mutagenesis of target lysines (Steffan et al.,
2004). From these studies, it was not clear which lysines are
preferentially SUMO modified. Based on SUMO prediction soft-
ware (SUMOplot, Abgent), the lysines in HTTex1p (Figure 1A) do
not fall within a classic SUMO consensus sequence but, rather,
are low-probability SUMO sites or not predicted (Figure 5A).
However, classic SUMO consensus sequences are neither
necessary nor sufficient for determining SUMO modification of
a protein. To directly determine which of the three N-terminal
lysines (K6, K9, or K15) are preferentially SUMO modified,
HTTex1p and lysinemutants, mutated singly and in combination,
were purified and analyzed using an in vitro SUMO modification
system followed bymass spectrometry analysis. SUMO-1 (t95R)
was used based on ease of detection of mono-SUMO modifica-
tion, and to minimize the confounding effect of aggregation,
unexpanded HTTex1p (25Q) constructs were used. When K6
and K9 were mutated singly to arginine (K6R, K9R), SUMOCell Reports 4, 362–375, July 25, 2013 ª2013 The Authors 363
modification is reduced compared to WT, but when K6 and K9
(K6,9R) are mutated together, SUMO modification is greatly
reduced, similar to the three lysine mutants (Figure 1B), suggest-
ing that K6 and K9 are the major target sites. Mass spectrometry
analysis confirmed that K6 and K9 are indeed the primary sites of
SUMO modification (Figure S1).
HTTex1p is subject to other posttranslational modifications
such as ubiquitination and phosphorylation (Ehrnhoefer et al.,
2011; Zheng and Diamond, 2012). Because (1) phosphorylation
modulates SUMOmodification of cellular proteins, (2) mimicking
phosphorylation of serines 13 and 16 (S13 and S16, respectively)
in expanded repeat HTTex1p (97QP) regulates SUMO-1 modifi-
cation in cells (Thompson et al., 2009), and (3) this modification is
relevant in vivo (Gu et al., 2009), we evaluated SUMO modifica-
tion of WT HTTex1p (25Q) in the context of a HTT phosphomimic
S13,16D in vitro. SUMO modification of the phosphomimetic
HTT (25Q) was equal to or more rapid than for WT HTT control
(Figure 1B); mass spectrometry analysis revealed that SUMO
modification of the S13,16D phosphomimic is restricted to K6
(Figure S1). These results suggest that both in vitro and in cells,
other posttranslational modifications, including phosphorylation,
may influence SUMO modification of HTT.
PIAS and SUMO Modification Proteins Are Highly
Expressed in Mouse Brain
Because SUMO E3 ligases provide specificity in targeting pro-
teins where a modified lysine does not fall within a consensus
site (Gareau and Lima, 2010), such as HTT, identifying the E3
ligase(s) that promotes HTT SUMOylation may be key to identi-
fying therapeutic targets that regulate this modification. Based
on the fact that PIASy was identified as a HTT-interacting protein
in a yeast two-hybrid (Y2H) screen (Goehler et al., 2004), we eval-
uated whether PIAS proteins could function as HTT E3 ligases. In
humans, the PIAS family consists of four members: PIAS1,
PIASx (xa and xb), PIAS3, and PIASy. Originally identified as
PIAS (Shuai and Liu, 2005), the PIAS proteins are involved in
regulation of transcription, immune responses, cytokine sig-
naling, and E3 ligase activity (Liu and Shuai, 2008; Rytinki
et al., 2009). As E3 ligases, they enhance SUMOylation of a num-
ber of different proteins, and multiple PIAS proteins can some-
times act as E3 ligases for the same substrate (Schmidt and
Mu¨ller, 2002).
To first establish that SUMOmodification enzymes are present
in brain regions relevant to HD, expression of SUMO-related pro-
teins was quantified in mouse striatum and cortex using quanti-
tative RT-PCR (qRT-PCR). SUMO-1, SUMO-2, PIAS, and SENP
mRNAs are all expressed in WT cortex and striatum. Within each
region, PIASx is most highly expressed, followed by PIAS1, with
PIAS3 and PIASy having similar expression profiles (Figure 2A).
This suggests that any PIAS could potentially serve as a HTT
E3 SUMO ligase based on its expression in vivo. The SENP pro-
teins are also expressed in the brain, with SENP6 most highly
expressed followed by SENP2 and SENP3, and finally SENP1
(Figure 2A). SUMO-1 and SUMO-2 are expressed in mouse brain
at relatively high levels. These data demonstrate that the SUMO
machinery is present in relevant brain regions.
To determine if these SUMO-related genes show expanded
repeat HTT-dependent alterations in expression patterns, each364 Cell Reports 4, 362–375, July 25, 2013 ª2013 The Authorswas quantified in WT and R6/2 mouse cortex and striatum at
4, 8, and 12weeks. R6/2mice express a truncated HTT fragment
(exon 1 with 150Qs) and show very rapid HD-like disease pro-
gression with onset by approximately 6 weeks, highly penetrant
phenotypes at 8 weeks, and end-stage disease by 12 weeks
(Mangiarini et al., 1996). At 4 and 8 weeks, some dysregulation
begins to occur (Figures S2A and S2B), and by 12 weeks, there
are statistically significant increases of SENP1, SENP3, and
SUMO-1 in R6/2 cortex and of SENP1, SENP6, PIAS3,
SUMO-1, and SUMO-2 in R6/2 striatum (Figures 2B and 2C),
suggesting that in vivo SUMO-modifying pathways may be
perturbed in HD. The increases in SUMO-1 and SUMO-2 specif-
ically in striatum, the region of greatest vulnerability to neurode-
generation, were particularly noteworthy. A similar pattern of
increased SUMO-2 in R6/2 striatum but not cortex was also
observed at the protein level (Figures 2D and 2E), suggesting a
SUMO-2-selective response in striatum. RNA was also isolated
from dissected brain regions of BACHD mice (Gray et al.,
2008) that express full-length human HTT as a BAC transgene
with 97Qs and show progressive disease over a longer time
course. SUMO-1 and SUMO-2 expression was similarly in-
creased in BACHD striatal samples at 14 months (Figure S2C),
a time when disease phenotypes are evident, and SUMO-2 is
increased in N171 mouse striatum at 12 weeks compared to
6 weeks (Jia et al., 2012). The progressive nature of these
changes, with the most robust observed at late disease stages,
is consistent with the concept of early changes in protein homeo-
stasis systems (Schipper-Krom et al., 2012) with later profound
disruption of the SUMO network at the gene expression and
protein level. Taken together, the most consistent change in
fragment and full-length mutant HTT mouse models is upregula-
tion of SUMO, suggesting that this pathway may be dysregu-
lated in vivo.
HTTex1p Is Modified by Both SUMO-1 and SUMO-2
Modification by SUMO-2 is unique in its capacity to be
induced by cellular stress (Saitoh and Hinchey, 2000). Based
on our previous data that the stress-inducible kinase IKK can
activate phosphorylation of HTT S13 and S16 and increase
polySUMOylation of 97QP HTTex1p (Thompson et al., 2009),
and given that oxidative stress and other cellular stressors are
implicated in HD (Browne and Beal, 2006), we investigated
whether SUMO-2 can modify HTT. A cell-based SUMOylation
assay was optimized to visualize and quantify SUMO modifica-
tion (Figure S3A; Extended Experimental Procedures), which
for endogenous proteins, is a highly dynamic process, and only
low levels of modification are typically observed for an individual
protein at any given time (Johnson, 2004). Expanded repeat
HTTex1p (46QP) with a C-terminal epitope tag (46QP-H4) was
cotransfected with SUMO-1 (GFP-SUMO-1) or SUMO-2 (GFP-
SUMO-2) and then purified under denaturing conditions using
magnetic nickel beads (Ni-NTA). SUMO-1 and SUMO-2 can
both modify HTTex1p, and when the lysines (K6, K9, and K15)
are mutated to arginine (3R), SUMO modification cannot be
detected (Figure 3A). An unusual laddering below control HTT
in the presence of SUMO-2, but not in the presence of lysine
mutants, is observed for this construct; however, the laddering
is not detected by anti-GFP, and its significance is not clear.
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Figure 2. SUMO-1 and SUMO-2 Are Differentially Expressed in HD Mice versus Control
(A) qRT-PCR analysis of SUMO-modifying proteins and enzymes in cortex and striata of WT mice at 12 weeks. Relative expression for all the SUMO enzymes is
normalized to mouse b-actin.
(B and C) qRT-PCR of SUMO mRNAs from 12-week-old WT and R6/2 mouse cortex (B) and striatum (C). SUMO enzyme mRNAs are differentially expressed in
R6/2 versus control with statistically significant increases in SENP1 (p = 0.01), SENP3 (p = 0.02), and SUMO-1 (p = 0.003) in cortex and SENP1 (p = 0.02), SENP6
(p = 0.04), PIAS3 (p = 0.007), SUMO-1 (p = 0.02), and SUMO-2 (p = 0.02) in striatum. Samples were analyzed in quadruplicate and normalized to mouse b-actin.
Data are shown as R6/2 expression relative to WT levels set at 1 for each enzyme with ± SD (n = 4). *p < 0.05. n.s., not significant.
(D and E) Western blot analysis of SUMO-2 in 14-week R6/2 cortex (D) and striatum (E) versus aged-matched controls. SUMO-2 is upregulated in R6/2 striatum
versus control (p = 0.026; n = 4). Protein is normalized to a-tubulin and quantitated using ImageJ.
Note that only the 12-week time point is shown in (B) and (C). Please see 4- and 8-week time points in Figures S2A and S2B.PIAS1 Is a Candidate SUMO E3 Ligase for HTT
Each of the PIAS proteins was evaluated for its ability to enhance
SUMOmodification of HTT, and the ratio of SUMO-modifiedHTT
versus purified HTT was quantified using a western blot imaging
system (Odyssey Imager; LI-COR). Because the PIAS proteins
are regulators of transcription, like SUMO, and can act as coac-
tivators and corepressors in addition to their E3 ligase activity
(Rytinki et al., 2009), one-tenth myc-actin under a CMV-based
promoter was cotransfected to account for transcriptional
effects (Thompson et al., 2009; Figure S3A). To control for differ-
ences in protein loading due to denaturing conditions precluding
protein assays, each membrane was stained with a reversible
protein stain (MEMCode). Finally, to control for differential HTT
expression, 10% of each sample was trichloracetic acid (TCA)
precipitated and subjected to western analysis. To demonstrate
that the modified form of HTT does indeed represent SUMO-
modified HTT, SUMO-1 was coexpressed in its mature, pro-cessed form (SUMO-1-GG) together with each of the SUMO
isopeptidase SENPs (SENP1, SENP2, SENP3, SENP5, and
SENP6) to show elimination by isopeptidases. SENP1, SENP2,
and SENP6 each catalyzed removal of SUMO-1 from HTT,
whereas SENP3 and SENP5 had no effect (Figure 3B), providing
validation that the shift in protein mobility represents SUMO-
modified HTT and suggesting selectivity of isopeptidase action.
To evaluate each PIAS protein for the ability to enhance HTT
SUMO modification, 46QP-H4 was coexpressed with SUMO-1
(GFP-SUMO-1) and each of the PIAS proteins (PIAS1, PIASxa,
PIASxb, PIAS3, and PIASy). HTT is readily modified by
SUMO-1 (Steffan et al., 2004) and (Figure 3A) at saturating levels
of SUMO-1. In order to detect enhancement of SUMO-1 modifi-
cation, a titration was performed to determine the SUMO-1 con-
centration at which modification of HTT was barely detectable
(Figure 3C) and the addition of a relevant E3 ligase could increase
HTT SUMOmodification (Stankovic-Valentin et al., 2007). PIAS1Cell Reports 4, 362–375, July 25, 2013 ª2013 The Authors 365
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Figure 3. HTT Is Modified by Both SUMO-1
and SUMO-2
(A) HeLa cells transfected with His-tagged
HTTex1p (46Q) or 46QP-K6,9,15R (3R) along
with GFP-SUMO-1 or GFP-SUMO-2, lysed under
denaturing conditions, and nickel purified (Ni-
NTA). Unmodified HTT-46Q is indicated by the
arrow and SUMO-modified HTT by the boxed re-
gion. The lysine mutant (3R) serves as a negative
control. Ni-NTA represents nickel-purified His-
tagged HTT, and WC TCA represents 10% of the
whole-cell lysate expression of HTT andmyc-actin
(transfection control). HTT is modified by SUMO-1
(left) and SUMO-2 (right).
(B) SUMO isopeptidases (SENP1, SENP2, SENP3,
SENP5, and SENP6) modulate SUMO-modified
HTT when overexpressed together with HTT
(46QP-H4 or 3R) and SUMO-1 (GFP-SUMO-1).
SENP1, SENP2, and SENP6 decrease HTT
SUMOylation. Graph depicts quantitation of
western blot using the Odyssey Infrared Imaging
System (LI-COR) to calculate the ratio of HTT
purified versus the HTT modified by SUMO multi-
plied by 100.
(C) Titration of SUMO-1. Denaturing nickel purifi-
cation of HTTex1p (46QP-H4) following trans-
fection with decreasing amounts of SUMO-1
reduces the amount of SUMO-modified HTT to
undetectable levels. The Ni-NTA blot displayed in
the gray scale shows purified HTTex1 and SUMO-
modified HTTex1 using HTT antibody. Note that
0.5 mg of SUMO-1 (¼ the amount of SUMO-1
cDNA ) was used for identifying the SUMO-1 E3
ligase for HTTex1p. Graph depicts quantitation of
western blot using the Odyssey Infrared Imaging
System to calculate the ratio of HTT purified versus
the HTT modified by SUMO multiplied by 100.
Note that all experiments were performed in trip-
licate, and a representative figure is shown.
See also Figure S3A.repeatedly enhanced SUMO-1 modification of HTTex1p (Fig-
ure 4A, representative figure), as did Rhes as previously reported
(Figure S3B).
We next investigated whether SUMO-2 modification of HTT
is also sensitive to the addition of an E3 ligase. Because
this modification is more difficult to visualize under basal condi-
tions, limiting SUMO-2 levels was not necessary. SUMO-2
was cotransfected with individual PIAS cDNAs, and PIAS1
was also most effective at enhancing SUMO-2 modification
of HTT (Figure 4B, representative figure). In this assay, Rhes
did not enhance the formation of a SUMO2-HTT species
(Figure S3C).
Consistent with its role as an E3 SUMO ligase and the under-
lying rationale that direct interactions between E3 ligases and
targets can promote SUMO modification, PIAS1 was evaluated
for its ability to bind to HTT fragments in vitro. Using GST pull-
down assays with HTT exon 1-encoding polypeptides, both
normal range (20QP) and expanded repeat HTTex1p(51QP)
interact strongly with PIAS1 (7.75% and 7%, respectively) (Fig-
ure 4C). As controls, protein lacking the protein-interacting
proline-rich domain of Htt (20Q and 51Q) or expressing the
proline-rich region alone showed greatly reduced interactions.366 Cell Reports 4, 362–375, July 25, 2013 ª2013 The AuthorsThese results suggest that a direct interaction between PIAS1
and HTTex1p may facilitate SUMO modification.
Longer HTT Fragments Are SUMOylated
A potentially critical and initiating cleavage event occurs at a
caspase-6 cleavage site of HTT (Graham et al., 2006), creating
a polypeptide of 586 amino acids (HTT 586 aa). Using bio-
informatic tools (SUMOplot; Abgent), five additional lysines
downstream of HTTex1p are predicted to be SUMOmodification
sites of high (two lysines) or lower (three lysines) probability (Fig-
ure 5A). Of interest, further analysis of the 586 aa fragment
reveals up to 13 potential overlapping SUMO-interacting motifs
(SIMs) within this region depending upon consensus sequence
designation (Figure 5A) (Tatham et al., 2008). SIMs are noncova-
lent interactions that may enhance SUMOylation of the SIM-con-
taining proteins themselves (Blomster et al., 2010). Therefore,
the SUMO and SIMs in HTT may work together to regulate
HTT SUMOylation.
To determine if longer HTT fragments are SUMOylated inde-
pendently of the lysines within the first 17 aa, HTT 586 aa con-
taining either an unexpanded (25Q-586 aa) or expanded polyQ
repeat (137Q-586 aa)was coexpressedwith SUMO-1 (Figure 5B)
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Figure 4. PIAS1 Is a SUMO E3 Ligase
for HTT
(A) Under limiting SUMO conditions (1/4 SUMO-1,
lanes 3–9), PIAS1 increases HTT-SUMO modifi-
cation above 1/4 SUMO alone. Purified HTT
(arrow) and SUMO-HTT (boxed region) were de-
tected using anti-HTT. Graph depicts quantitation
of the Ni-NTA western blot using the Odyssey
Infrared Imaging Software (LI-COR) to calculate
the ratio of HTT purified versus the HTT modified
by SUMO multiplied by 100.
(B) Western analysis of overexpression of HTTex1
(46QP-H4 or 3R), SUMO-2 (GFP-SUMO-2), and all
the PIAS proteins (PIAS1, PIASxa, PIASxb, PIAS3,
and PIASy). Under nonlimiting SUMO-2 condi-
tions, PIAS1 enhances SUMOmodification of HTT.
WC TCA shows overall myc-actin (transfection
control) and HTT levels. Graph quantitating the
ratio of HTT purified versus the HTTmodified using
the Odyssey (LICOR).
(C) Left panel is the autoradiography results of a
GST pull-down assay showing that radiolabeled
human PIAS1 interacts with HTTex1p. Right panel
is a phosphorimager analysis of GST pull-downs,
performed in triplicate, showing the percentage of
35S-labeled PIAS protein that bound the GST
proteins: GST alone, unexpanded HTT with and
without the proline-rich region (20QP and 20Q),
expanded HTT with and without the proline-rich
region (51QP and 51Q), and the proline-rich region
alone (Pro). Error bars were calculated as an esti-
mate of SE = STDEV(n)/SQRT(n-1).because this modification should be detected under basal
conditions. As a control, HTT 586 aa constructs with K6,9,15R
mutations that diminish SUMO modification within the first
17 aa were tested. Immunoprecipitated HTTex1p (46QP-H4) is
monoSUMOylated by SUMO-1 (Figure 5B), but the 3R mutant
form is not modified as expected. However, other lysines down-
stream of this amino-terminal domain can also be SUMOylated
because SUMO-1modification is observed even in the presence
of the K6,9,15R mutation in either its expanded or unexpanded
forms.
PIAS1 Increases SUMO-2 Modification of HTT 586 aa
SUMO-2 modification of HTT 586 aa is not detected in the
absence of external stimuli (Figure 5E); therefore, longer HTT
fragments were evaluated for SUMO-2 modification in the pres-
ence of an E3-SUMO ligase. Potential interactions between
longer HTT fragments and E3 SUMO ligases were first investi-
gated using a large-scale Y2H screen. Here, the 586 aa fragment
of HTT was used as bait, and PIAS1 emerged as the single E3
SUMO ligase interaction partner (Figure 5C), supporting its rele-
vance even for longer HTT polypeptides. Previously identified
interactors were also tested in this system and confirmed,
including HIP2 and GIT1 (Goehler et al., 2004). To further validate
this interaction in vitro, coimmunoprecipitation of HTT from cell
lysates transfected with HTT (25Q-586) and PIAS1 with or
without cotransfected SUMO-1 was tested. PIAS1 binds both
transfected HTT (586 aa) and full-length endogenous HTT based
on PIAS1 detection even in the absence of exogenous HTT 586overexpression (Figure 5D). SUMO-2 modification of longer HTT
polypeptides was therefore tested in the presence of PIAS1.
Based on in vitro results (Figure 1B) and because SUMO-2 is
stress inducible similar to the signal transduction cascades
that modulate HTT phosphorylation, S13, 16D phosphomimic
polypeptides were also tested. Expanded repeat HTT 586 aa
fragments are SUMO-2 modified in the presence of PIAS1, and
this modification is enhanced by mimicking phosphorylation
(S13, 16D-586 aa) for both expanded and unexpanded HTT
586 aa (Figures 5E and 5F).
SUMO-2 Promotes Accumulation of Insoluble
Mutant HTT
Emerging data suggest that SUMOylation may influence aggre-
gation and accumulation of aggregation-prone neurodegenera-
tive disease proteins (Kim et al., 2011; Tatham et al., 2011). To
address the functional consequences of SUMO modification
of mutant HTT on disease, the involvement of SUMO-1 and
SUMO-2 modification on the formation of insoluble HTT species
was evaluated in HeLa cells, where SUMOmodification systems
are highly active. Our previous studies evaluated visible inclusion
formation and levels of soluble mutant HTT and showed that
fusion of SUMO to the HTTex1p N terminus promoted stabiliza-
tion of HTTex1p (Steffan et al., 2004). However, we and others
have since identified the HTTex1p N terminus as an important
mediator of aggregation, localization, and protein stability (Atwal
and Truant, 2008; Rockabrand et al., 2007; Sivanandam et al.,
2011; Thompson et al., 2009; Zheng et al., 2013), which mayCell Reports 4, 362–375, July 25, 2013 ª2013 The Authors 367
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Figure 5. A 586 aa Fragment of HTT Is
SUMO Modified Downstream of Exon 1
(A) SUMOplot (Abgent) predicts that HTT is
SUMOylated downstream of HTTex1p lysines.
SUMOplot analysis predicts two high-probability
SUMO sites (red) and three low-probability SUMO
sites (blue) identified downstream of HTT exon 1.
Greater than 13 overlapping noncovalent SIMs are
observed within this fragment (yellow).
(B) Longer HTT polypeptides are modified by
SUMO-1. Western blot overexpressing HTTex1p
(46QP-H4 or 3R), unexpanded HTT-586 fragment
(25Q-586 or 25Q-3R-586 aa), and expanded HTT-
586 fragment (137Q-586 or 137Q-3R-586 aa) with
SUMO-1 (GFP-SUMO-1). Cell lysates were sub-
jected to HTT immunoprecipitation (IP) using HTT
antibody. Western analysis performed with the
Odyssey (LI-COR) allows detection of HTT (data
not shown) and SUMO simultaneously and shows
that all forms of HTT are SUMO-1 modified using
the anti-GFP antibody. HTTex1p is covalently
SUMO-1 modified (lane 3), and the modification
disappears when Lys are mutated to Arg (3R)
(lane 4). Both unexpanded (lane 4 and 5) and
expanded HTT-586 fragments (lane 6 and 7) are
covalently SUMO-1 modified in both the presence
and absence of the three Lys in the N-terminal
region of HTT (3R). Free SUMO-1 is indicated with
the arrow, and SUMO-modified HTT is indicated
by the boxes. Inset on the right, from a replicate
experiment, shows comigration of expanded HTT
(anti-HTT) and SUMO-1 (anti-GFP) displayed in
the gray scale and in color when the two anti-
bodies are merged (HTT in red, SUMO-1 in green,
and yellow when colocalizing).
(C) Bait plasmids (HTT-586-25Q or HTT-586-73Q
aa) were transformed into the L40ccua MATa
yeast strain. Yeast clones encoding bait proteins
were individually mated against a matrix of MATa
yeast clones encoding 16,888 prey proteins (with
Gal4 activation domain fusions) using pipetting
and spotting robots. Diploid yeasts were spotted
onto SDIV (-Leu-Trp-Ura-His) agar plates for selection of PPIs as well as nylonmembranes placed on SDIV agar plates for b-galactosidase assays. After 5–6 days
of incubation at 30C, digitized images of the agar plates and nylon membranes were assessed for growth and b-galactosidase activity using the software Visual
Grid (GPC Biotech).
(D) Overexpression of PIAS1 alone, with unexpanded HTT constructs (25Q-586 aa) plus SUMO-1 (GFP-SUMO-1), shows that PIAS1 binds both full-length HTT
and HTT-586 fragment (25Q-586 aa). WT HTT was used in these experiments to preclude confounding aggregation effects. Western analysis detection was
performed using Odyssey and is displayed in the gray scale but is shown in color on the merge (HTT is red, and PIAS1 is green). WB, western blot.
(E) HeLa cells overexpressing either expanded 586 aa-HTT or the phosphomimetic (S13,16D = DD) with SUMO-2 plus and minus PIAS1. HTT was purified by IP
using hydrazide beads (Bioclone) crosslinked to HTT (Enzo) antibody and subjected to western analysis using anti-HTT (MAB5490). Arrows indicate SUMO-2-
modified HTT.
(F) IP of HTTwith hydrazide-linked beads shows that both unexpanded and expanded HTT 586 aa phosphomimetics (S13, 16D-586 aa) aremodified by SUMO-2.
Arrows indicate SUMO-conjugated HTT. Note that all experiments including the Y2H assaywere done in triplicate; representative experiments are shown. Arrows
indicate SUMO-2-modified HTT.have been masked by the presence of the SUMO moiety.
SUMO-1 also decreased mutant HTT aggregation in the pres-
ence of Rhes and increased toxicity in cells (Subramaniam
et al., 2009). In each case, only SUMO-1 was evaluated.
For HD, the process of aggregation and specific aggregation
intermediates are likely to be critical to pathogenesis. Using a
centrifugation protocol published for a-synuclein (Kim et al.,
2011), lysates were separated into detergent-soluble and
detergent-insoluble fractions. The detergent-soluble fraction
contains monomeric HTT, which includes overexpressedmutant368 Cell Reports 4, 362–375, July 25, 2013 ª2013 The AuthorsHTTex1p (97Q) and endogenous full-length HTT (indicated by
arrows in Figure 6A, SOLUBLE fraction). In contrast, the deter-
gent-insoluble fraction contains only high molecular weight
(HMW) HTT in the samples containing 97Q-HTTex1p (Figure 6A,
INSOLUBLE fraction), which are likely multimers or potentially
oligomers of soluble HTT.
MG132 is a proteasomal inhibitor that causes the accu-
mulation of mutant HTT in cells (Lee and Goldberg, 1998). To
investigate the relationship between proteasomal degradation
and SUMO modification and to analyze levels of soluble and
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Figure 6. SUMO-2 Causes Mutant HTT to
Accumulate
(A) Western analysis of whole-cell lysates from
HeLa cells transfected with His-SUMO-1 or
SUMO-2 and/or 97Q-HTT exon 1 and treated with
5 mM MG132 for 18 hr. Lysates were separated
using differential centrifugation into a detergent-
soluble fraction (SOLUBLE) with 1% Triton X-100
and a detergent-insoluble fraction (INSOLUBLE)
with 4% SDS. Western blot probed with anti-
HTT shows full-length endogenous HTT in the
SOLUBLE fraction (upper arrow) and 97Q-HTTex1
(lower arrow) (left panel). In the INSOLUBLE frac-
tion, HTT HMW species are indicated by the
bracket and asterisks (right panel).
(B) MG132 and SUMO-2 cause mutant HTT to
accumulate as HMW species (bracket and
asterisk). Western blot showing IP with HTT
antibody crosslinked beads from the detergent-
insoluble fraction probed with the anti-HTT
antibody.
(C) Mutant HTT (97Q-Httex1) fibrils are detected
with anti-HTT in the insoluble fraction with treat-
ment of MG132 or addition of exogenous
SUMO-2.
(D) Western blot with increasing concentrations
of SUMO-2 detected with anti-His antibody (left
panel). Middle panel is the same western blot
probed with anti-HTT showing soluble forms of
HTT. Right panel presents western blot from
detergent-insoluble fraction with monomeric HTT
(97Q) at 55 kDa, and the asterisk (*) indicates the
HMW species. Note that all experiments were
performed in triplicate; representative figures are
shown.insoluble HTT species in the presence of SUMO-1 and SUMO-2,
HeLa cells were transiently transfected with 97Q-HTTex1p and
treated with MG132 (5 mM). Treatment with MG132 causes a
robust increase in HMW mutant HTT in the insoluble fraction
(Figure 6A), with accumulation of ubiquitin-modified cellular pro-
teins (data not shown). In contrast, soluble, monomeric HTT
levels are maintained or slightly decreased (Figure 6A), support-
ing the concept that impairment of proteasomal function in-
creases levels of aggregating HTT. Immunoprecipitation was
performed to increase HTT detection. Addition of SUMO-1 had
little to no additional effect on soluble HTT or insoluble HMW
HTT levels (Figures 6B and 6C). However, the addition of
SUMO-2 caused an increase in insoluble HTT (Figures 6B and
6C) that was comparable to proteasome inhibition. This effect
is not augmented by combined SUMO-2 expression and protea-Cell Reports 4, 362–some inhibition, suggesting that SUMO-2
modulates accumulation and aggrega-
tion of mutant HTT in a manner that
mimics proteasome inhibition. This
regulation of insoluble HTT levels by
SUMO-2 is dose dependent. When cells
were treated with increasing amounts of
SUMO-2, verified by increasing levels of
mono-SUMO-2 by western analysis (Fig-ure 6D, boxed in first panel), increasing levels of HMW HTT
were observed, whereas monomeric levels showed a corre-
sponding decrease in the insoluble fraction, potentially reflecting
insoluble monomeric HTT levels.
Because SUMO-2 modulates HMW HTT species and
SUMO-2 modification of HTT appears to require the presence
of a SUMO E3 ligase, we tested whether PIAS1 alone can
modulate mutant HTT accumulation. When PIAS1 was over-
expressed in the presence of expanded repeat HTT with
97Qs, the detergent-insoluble HTT HMW ‘‘oligomeric’’ species
increased, whereas soluble HTT appeared to be unaffected
(Figure 7A), and a reduction of the HMW oligomeric HTT species
is observed following PIAS1 acute knockdown (Figure 7B).
Taken together, these data demonstrate that PIAS1 can regulate
the accumulation of insoluble HMW HTT polypeptide species,375, July 25, 2013 ª2013 The Authors 369
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B Figure 7. SUMO-2 Proteins Accumulate in
HD Brain
(A) Western blot analysis of HeLa cells over-
expressing exogenous PIAS1 in the presence of
mutant HTT (97Q) when separated into detergent-
soluble and detergent-insoluble fractions. No dif-
ference is detected in monomeric HTT (top panel,
Soluble), but HMWHTT levels increase with PIAS1
overexpression. Anti-PIAS1 antibody (Invitrogen)
was used to detect PIAS1.
(B) Acute knockdown of PIAS1 decreases HMW
HTT species in the detergent-insoluble fraction.
PIAS1 knockdown is detected in detergent-soluble
and -insoluble fractions using anti-PIAS1 antibody.
(C) Drosophila melanogaster expressing mutant
HTTex1p (93Q) in a reduced Su(var)2-10/dPIAS
genetic background exhibits statistically signifi-
cantly reduced photoreceptor neuron degenera-
tion (left panel, p = 0.033) when comparing
dPIAS/+ to +/+ flies and increased overall survival
(right panel, p = 0.047) when comparing dPIAS1/+
to +/+ flies. Significance was measured by
Student’s t test.
(D) HMW SUMO-2 accumulates in postmortem
HD striata. Western blot analysis of the
insoluble fraction from three control and three HD
postmortem striata as described (Experimental
Procedures).suggesting that modulation of PIAS1 may influence pathogen-
esis in HD.
Genetic Reduction of Su(-var)2-10 Is Neuroprotective in
Mutant HTTex1p-Expressing Drosophila
To validate the potential involvement of PIAS proteins in HD
pathogenesis in vivo, the single Drosophila PIAS protein,
Su(-var)2-10 (dPIAS) (Hari et al., 2001), was evaluated for its
effect on HD-like phenotypes in a fly model (Steffan et al.,
2001). When expressed in all neurons from embryogenesis on,
expanded repeat HTTex1p (93Q) causes a progressive loss of
visible rhabdomeres (photoreceptor neurons in the eye) (Marsh
and Thompson, 2006) and a decrease in the number of flies
that eclose from the pupal case as adult flies (Figure 7C).
When expressed in a background of heterozygous genetic
reduction of dPIAS, the number of visible photoreceptor neurons
and survival (eclosion) are both increased (Figure 7C). The
observed neuroprotection is not simply a consequence of370 Cell Reports 4, 362–375, July 25, 2013 ª2013 The Authorsdecreased transgene expression based
on analysis of HTT RNA by qPCR (data
not shown). These results are consistent
with our previous observations showing
that reduction of Drosophila SUMO
(smt3) was protective in this same model
(Steffan et al., 2004).
Insoluble SUMO-2-Modified
Proteins Are Increased in Human
HD Brain
To investigate whether SUMO-modified
proteins accumulate in HD brain tissuecompared to control subjects and whether SUMO-1 or
SUMO-2 has selective effects, postmortem striata from three
control and three HD brains were evaluated. Each of the HD
subjects displayed a remarkable accumulation of SUMO-2-
modified protein compared to controls in insoluble fractions (Fig-
ure 7D). To a lesser extent, accumulation of SUMO-1 is also
observed. Differences in the levels of SUMO-2-modified protein
do not correlate with ubiquitin reactivity in control and HD
brain fractions but, rather, appear to be specific for SUMO.
Although we cannot conclude from these data that the increased
SUMO-2 reactivity represents an increase in mutant HTT
SUMO-2 modification per se, a HTT antibody raised against aa
115–129 shows a similar pattern of increased HMWHTT species
in HD samples compared to controls (Figure 7D), suggesting that
HTT is included in the proteins that accumulate in HD striata.
Taken together, these results support SUMO-2 relevance in
HD pathology and that SUMO-modifying enzymes may be valid
therapeutic targets.
DISCUSSION
SUMOmodification contributes to an impressive array of regula-
tory mechanisms that have critical biological functions (Bruderer
et al., 2011). In turn, dysregulation of this cellular process is impli-
cated in diseases ranging from cancer to neurological disease
(Gareau and Lima, 2010). Although SUMO modification is tran-
sient, downstream consequences are long lasting and impact
processes such as protein folding, subcellular localization, sta-
bility, transcriptional regulation, and protein activity (Geiss-
Friedlander and Melchior, 2007), all of which are affected in HD
(Zheng and Diamond, 2012). Implicating a role in neurodegener-
ative diseases, a growing number of causative neurodegenera-
tive disease proteins either colocalize with SUMO molecules or
are target proteins for SUMO modification (for review, see Kru-
mova and Weishaupt, 2013; Wilkinson et al., 2010). To date,
the primary mechanisms involve altered solubility of or visible
inclusion formation by these disease proteins, with ensuing pro-
tective (SBMA), deleterious (SCA7), or mixed effects (a-synu-
clein), depending on the protein context and form of SUMO
tested. Enzymes involved in these processes, such as Rhes,
are beginning to emerge (Oh et al., 2011; Subramaniam et al.,
2009).
Here, we demonstrate that SUMO-2 modification of HTT, a
stress-responsive modification pathway not previously investi-
gated for HTT, regulates the accumulation of insoluble mutant
HTT. This SUMO form is consistently upregulated in striata
from several HDmousemodels, at a stage of disease anticipated
to display significant dysregulation of protein homeostasis
network components. Furthermore, PIAS1, which selectively
enhances HTT SUMO-1 and SUMO-2 modification and is ex-
pressed in brain, is integral to this accumulation. The functional
relevance of these findings is further validated by (1) the neuro-
protection observed upon reduction of the single Drosophila
PIAS (dPIAS), which is most similar to PIAS1 (Hari et al., 2001),
in flies expressing a mutant fragment of HTT, and (2) the pro-
found accumulation of SUMO-2-modified HMW protein in hu-
man HD brain. The finding that the stress-responsive SUMO-2
is likely most relevant to HD pathogenesis over basal SUMO-1
modification by regulating the accumulation of HMW and likely
poly-SUMOylated protein is consistent with the prevailing litera-
ture that chronic expression of mutant HTT causes cellular
stress, including oxidative stress (Turner and Schapira, 2010).
This cellular stress, which is likely progressive and could there-
fore promote stress responses, including SUMO-2 modification,
could then contribute to disease. Validation of SUMO-2 involve-
ment in response to neuronal stressors has recently emerged in
several systems, including APP overexpression in AD mice
(McMillan et al., 2011), transient cerebral ischemia in brains of
ground squirrels (Lee et al., 2012), and transient ischemia in cells
(Yang et al., 2012), in some cases, promoting a neuroprotective
response to ischemic stress (Datwyler et al., 2011).
We previously reported that mimicking phosphorylation of
S13 and S16 reduces monoSUMOylation and increases
polySUMOylation of mHTTex1p with a highly expanded 97Q
repeat (Thompson et al., 2009). Here, we confirm that K6 and
K9within the first 17 aa domain are indeed SUMO-1modification
sites even though these lysines do not lie within classic SUMOconsensus sequences. Intriguingly, SUMO-1 is conjugated to
K6 and K9 equivalently in the absence of other modifications,
whereas phosphomimetic substitutions of S13 and S16 appear
to block SUMO modification on K9 or promote SUMO-1 modifi-
cation on K6, which may be significant to regulation of other HTT
modifications, such as K9 acetylation. In cells, mimicking phos-
phorylation at these sites enhances SUMO-2 modification in the
presence of a relevant E3 SUMO ligase. Given that phosphoryla-
tion of HTT is responsive to inflammatory cues (Thompson et al.,
2009), that PIAS1 is involved in immune function, and that inflam-
mation is increased in HD (Bjo¨rkqvist et al., 2009; Khoshnan
et al., 2004), it is likely that SUMO-2 modification is also respon-
sive to inflammatory cues that appear early in HD.
A key feature in HD is the accumulation of mutant HTT frag-
ments containing the polyQ expansion (Landles et al., 2010).
WT and mutant HTT can be cleaved by caspases, calpains,
and aspartyl proteases to form N-terminal fragments (Warby
et al., 2008), which become toxic when in the context of the
expanded polyglutamine repeat. Studies in mice expressing a
caspase-6-resistant form of mutant HTT suggest that HTT prote-
olysis specifically at 586 may be critical to HD pathogenesis
(Graham et al., 2006; Warby et al., 2009), and overexpression
of transgenic-expanded repeat HTT 586 supports potential
toxicity of this fragment (Waldron-Roby et al., 2012). Analysis
of longer polyQ polypeptides revealed that unexpanded and
expanded HTT 586 fragments are SUMOylated downstream of
HTTex1p. The caspase-6 cleavage fragment of HTT (586 aa)
has five predicted SUMOylation sites C-terminal to exon 1,
with potentially greater than 13 overlapping SIMs within this re-
gion, depending on the SIM evaluated. SIMs are noncovalent
protein-protein interactions that have recently emerged as
having critical regulatory properties (Gareau and Lima, 2010).
For example, the ubiquitin ligase RNF4 has multiple SIMs that
recognize polySUMO-2 chains and ubiquitinate them for degra-
dation by the proteasome (Geoffroy and Hay, 2009; Tatham
et al., 2008). Indeed, these SIMs may be important signal trans-
duction inducers downstream of polySUMOylation events (Sun
and Hunter, 2012). SIMs within target proteins can also enhance
their SUMOmodification and are found within several E3-SUMO
ligases, including PIAS1 (Gareau and Lima, 2010). The implica-
tions of these multiple SIMs in HTT are not yet clear; however,
we are actively pursuing this area of investigation.
The interplay between SUMO-2 and proteasome inhibition is
consistent with recent proteomic analysis of extracts from
HeLa cells treated with MG132 to identify SUMO-2-modified
proteins (Tatham et al., 2011). In these studies, all SUMO paral-
ogs accumulated upon treatment with MG132; however the
greatest response exhibited was by SUMO-2, suggesting that
SUMO modification of cellular proteins is not only involved in
regulating proteostasis of unfolded and misfolded proteins
within a cell but may in fact represent a response to the presence
of misfolded or oligomerized proteins, such as mutant HTT, and
be involved in protein clearance mechanisms. This hypothesis is
supported by studies showing that the presence of mutant HTT
polypeptide alone in C. elegans can cause the misfolding and
inactivation of temperature-sensitive mutant proteins to a similar
degree as heat shock (Gidalevitz et al., 2006). These findings
suggested that mutant HTT protein expression is sufficient toCell Reports 4, 362–375, July 25, 2013 ª2013 The Authors 371
impact the protein homeostatic network and relevant to the
work described here, accumulation of SUMO-2-modified cellular
proteins. Furthermore, when the production of misfolded pro-
teins exceeds the capacity of the chaperone and UPS systems,
mimicked here by proteasome/cathepsin inhibition by MG132,
then these proteins may be targeted for degradation by
autophagy, which also becomes impaired late in disease. As
protein clearance mechanisms become impaired upon aging,
modified proteins normally targeted for degradation by post-
translational modification, such as phosphorylation and acetyla-
tion, may accumulate and take on toxic functions. Supporting
this concept, proteasome inhibition promoted formation of
aggregates containing SUMO-modified a-synuclein (Kim et al.,
2011).
In summary, the work presented here supports a general
mechanism in HD whereby the chronic expression of expanded
repeat HTT promotes general protein misfolding and initiation of
stress response pathways that promote SUMO-2modification of
HTT, progressively resulting in accumulation of insoluble and
HMW species that may be a reflection of ongoing pathogenesis.
In addition, loss of normal HTT functions may also contribute
to the accumulation of SUMOylated proteins (Steffan, 2010).
Initially, SUMO-2 modification and polySUMOylation are likely
to facilitate normal cellular clearance mechanisms with integra-
tion between SUMOylation and ubiquitination and serve in a neu-
roprotective capacity; however, these are likely to become toxic
as pathways become impaired and these species accumulate
and cause further disruption of overall cellular protein homeosta-
sis, reflected here by increased expression and level of SUMO-2
and other SUMO modification cellular components. This is
demonstrated by the accumulation of SUMO-2 protein in a
HMW insoluble fraction from human HD striatum, the region
most profoundly affected in HD. We further identify a HTT E3-
SUMO ligase, PIAS1, which is expressed in relevant brain re-
gions and appears to have a pivotal role in the regulation of
SUMO-2-modified HTT, providing a novel and selective thera-
peutic target.
EXPERIMENTAL PROCEDURES
Plasmids
Plasmid generation is described in the Supplemental Information.
siRNA
siRNA against PIAS1 and a nontargeting control were purchased from Dhar-
macon (Thermo Scientific) and include PIAS1-ON-TARGETplus SMARTpool
(L-008167-00-0005), Human PIAS1, NM_016166, and ON-TARGETplus Non-
targeting siRNA #1 D-001810-01-20.
Primary Antibodies
Anti-HTT (Enzo Life Sciences) antibody was generated in collaboration
with England Enzo Life Sciences UK (Palatine House, Matford Court,
Exeter). The following antibodies were also used: anti-HTT (MAB5490)
and anti-HA.11 Clone 16B12 monoclonal (Covance); anti-Myc 9E10
(Millipore); anti-EGFP detected by Living Colors Full-Length Monoclonal Anti-
body (Clontech; JL-8); anti-mPIAS1 (Invitrogen); anti-SUMO-1 (Enzo Life
Sciences); anti-SUMO-2 (MBL International); and anti-ubiquitin (Santa Cruz
Biotechnology).
GST Pull-Down Assays
Assays were performed as previously described (Steffan et al., 2000).372 Cell Reports 4, 362–375, July 25, 2013 ª2013 The AuthorsIn Vitro SUMO Modification
The expression and purification of human E1 (SAE1/UBA2DCT), E2 (UBC9),
IR1* (RanBP2, aa 2,631–2,695), and mature SUMO-1 have been previously
described (Bernier-Villamor et al., 2002; Lois and Lima, 2005; Olsen et al.,
2010; Reverter and Lima, 2005).
Mass Spectrometry
SUMO-1 T95R was generated by PCR mutagenesis (QuikChange Site-
Directed Mutagenesis Kit; Stratagene) to introduce a trypsin cleavage site
near the SUMO C terminus and purified as described for SUMO-1. Reactions
containing 200 mM SUMO-1 T95R, 200 mM HTT (WT or S13,16D), 200 nM E1,
200 nM E2, and 2 mM IR1* in reaction buffer (20 mM HEPES [pH 7.5], 50 mM
NaCl, 5 mMMgCl2, 1 mMDTT, 1 mM ATP, and 0.01% Tween 20) were incu-
bated at 37C, and aliquots were removed at 0 and 60 min. Samples were en-
riched by incubation with Ni-NTA beads (QIAGEN) and eluted with loading
buffer containing 100 mM EDTA. Samples were resolved by SDS-PAGE and
stained with Coomassie blue. Bands corresponding to HTT and SUMO-
modified HTT were submitted for analysis by mass spectrometry (Extended
Experimental Procedures).
Cell Culture
HeLa cells were plated on 10 cm plates and cultured in DMEM plus 10% FBS.
For cDNA only, cells were plated on day 1 and transiently transfected with 6 mg
of total DNA and 8 ml Lipofectamine 2000 (Invitrogen) on day 2, media were
changed on day 3, and cells were collected on day 4. For siRNA only, transient
transfections were carried out as described above, except that 720 pmol
siRNA and 36 ml of RNAi Max were used. For combined siRNA and cDNA ex-
periments, cells were transfected with siRNA, media were replaced on day 2,
and cDNA was transfected 12 hr after siRNA. Days 3 and 4 are as described
above. Cells were transfected at 70% confluency for DNA and 30%–
50% confluency for siRNA.
Western Blot Analysis
A total of 8% bis-acrylamide gels and Invitrogen 4%–12% bis-tris mini gels
were used for SDS-PAGE, proteins were transferred to nitrocellulose mem-
brane, and nonspecific proteins were blocked with SuperBlock Blocking
Buffer (Thermo Scientific). Two types of detection were used: chemilumines-
cence/film, or Odyssey Imager/LI-COR (Extended Experimental Procedures).
Experiments were performed in triplicate with representative images shown.
Nickel Purifications
His-tagged HTT proteins were purified using magnetic Ni-NTA nickel beads
(QIAGEN). For in vitro SUMOylation assays, ST14.A cells were transfected
with the 25QP-HBH constructs into 25 10 cm plates per construct and puri-
fied under native conditions using the recommended buffers from QIAGEN
(lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.05% Tween
20 [pH 8]; wash buffer: 50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole,
0.05% Tween 20 [pH 8]). For denaturing SUMO cell culture assay, HeLa cells
were transfected and purified under denaturing conditions using the recom-
mended buffer from QIAGEN (lysis buffer: 6 M guanidine HCl, 0.1 M NaH2PO4,
10 mM Tris-Cl [pH 8]; Wash Buffer #1: 8 M urea, 100 mM NaH2PO4, 10 mM
Tris-Cl [pH 8]; and Wash buffer #2: 8 M urea, 100 mM NaH2PO4, 10 mM
Tris-Cl [pH 6.3]). Of each lysate, 10% was subjected to TCA precipitation.
For the nickel purification, 50 ml of magnetic bead slurry was added to each
sample and incubated at room temperature for 3 hr. Beads were collected
on the magnetic rack, washed two times with Wash Buffer #1 (8 M urea
[pH 8]), one time with Wash Buffer #2 (8 M urea [pH 6.3]), and one final time
with 13 PBS. Washed beads were submerged in 23 Laemmli sample buffer,
boiled for 10 min, and analyzed using western analysis. Each experiment was
performed in triplicate, and a representative figure is shown.
Immunoprecipitations
HeLa cells were lysed in buffer containing 50 mM Tris-HCl [pH 8], 150 mM
NaCl, 1% NP40 alternative, a mini protease inhibitor pellet (Roche), 2 mM
DTT, and 25 mM N-ethylmaleimide (NEM) (Ulrich, 2009). HTT protein was
either precipitated using protein G plus from Santa Cruz or hydrazide-link
beads from Bioclone.
Soluble/Insoluble Fractionation
HeLa cells were collected in lysis buffer containing 10 mM Tris (pH 7.4), 1%
Triton X-100, 150 mM NaCl, 10% glycerol, and 0.2 mM PMSF (Roche
Complete Protease Mini and PhosphoStop pellets). Cells collected were lysed
on ice for 60 min before centrifugation at 15,0003 g for 20 min at 4C. Super-
natant was collected as the detergent-soluble fraction. The pellet was washed
33 with lysis buffer and centrifuged at 15,000 3 g for 5 min each at 4C. The
pellet was resuspended in lysis buffer supplemented with 4% SDS, sonicated
33, boiled for 30 min, and collected as the detergent-insoluble fraction.
Protein concentration was quantitated using Lowry Protein Assay (Bio-Rad)
Soluble/insoluble fractionation protocol was previously described (Kim et al.,
2011).
Filter Retardation Assay
A total of 30 mg of detergent-soluble and detergent-insoluble protein in 200 ml
of 2% SDS was boiled for 5 min and run through a dot blot apparatus under a
vacuum onto a cellulose acetate membrane. Membrane was then washed 33
with 0.1% SDS and then blocked in 5%milk and subject to western blot anal-
ysis (previously described by Sontag et al., 2012; Wanker et al. 1999).
RNA Isolation and Real-Time Quantitative PCR
Cortex and striatum were dissected from 4-, 8-, and 12-week-old female WT
and R6/2 mice. At King’s College London, hemizygous R6/2 mice were bred
by backcrossing R6/2 males to (CBA 3 C57BL/6) F1 females (B6CBAF1/
OlaHsd, Harlan Olac, Bicester) and maintained as previously described by
Labbadia et al. (2011). The CAG repeat was 204.7 ± 5.8. Brain tissues were
homogenized in TRIzol (Invitrogen), and total RNA was isolated using RNEasy
Mini kit (QIAGEN). DNase treatment was incorporated into the RNEasy proce-
dure in order to remove residual DNA. Reverse transcription was performed
using oligo (dT) primers and 1 mg of total RNA using SuperScript III First-
Strand Synthesis System (Invitrogen). Quantitative PCR (qPCR) was per-
formed (Table S1).
Automated Y2H Screening
GATEWAY technology (Invitrogen) was used to subclone 25Q-586 and 73Q-
586 aa cDNAs encoding human HTT fragments into Y2H expression plasmids.
‘‘Gateway compatible’’ cDNAs encoding selected proteins were generated by
PCR amplification. Amplified DNA products were isolated from agarose gels
and combined with the pDONR221 plasmid (Invitrogen), creating the desired
entry DNA plasmids. The identity of all PCR products was verified by DNA
sequencing. Subsequently, utilizing LR recombination, pBTM116_D9 plas-
mids (for the production of LexA DNA-binding domain fusions) were generated
encoding HTT bait proteins for automated Y2H interaction mating. The identity
of the plasmids was verified by BsrGI restriction digestion. Bait plasmids were
transformed into the L40ccua MATa yeast strain, and yeast clones were indi-
vidually mated against a matrix of MATa yeast clones encoding 16,888 prey
proteins (with Gal4 activation domain fusions) using pipetting and spotting
robots. The automated Y2H screenings were repeated three times. Interaction
mating experiments and imaging were performed as described previously by
Stelzl et al. (2005).
Drosophila Crosses
Flies were reared on standard cornmeal molasses medium at 25C. To com-
pare phenotypes of HTT-expressing animals in a normal versus a Su(var)2-
10 (dPIAS)-reduced background, w/w; +/+; UAS > HTTex1p-Q93/UAS >
HTTex1p-Q93 females were crossed to elav-GAL4/Y; Su(var)2-10[zimp-2]/
Sp males. Eclosion data from R1,500 segregants were calculated as a per-
centage of elav-GAL4/+; Su(var)2-10/+ HTT/+ or elav-GAL4/+; +/Sp; HTT/+
flies versus HTT-nonexpressing male siblings. Pseudopupil analysis was car-
ried out on 7-day-old flies as described (Steffan et al., 2001).
Human Postmortem Brain
Human autopsy brain tissue, from the striatum of control and patients with HD,
was obtained from individuals with ages at autopsy from 72 to 93 years of age
and grades 3–4 and flash frozen with postmortem intervals ranging from 13 to
22 hr. Frozen human brain tissue was homogenized on ice using T-PER Tissue
Protein Extraction Reagent (Thermo Scientific) containing a complete minipellet (Roche), phosphatase inhibitor #1 (Sigma-Aldrich), phosphatase inhibi-
tor #2 (Sigma-Aldrich), and 25 mM NEM. Lysates were ultracentrifuged at
45,000 rpm at 4C for 60 min, and the pellet was homogenized on ice in
70% formic acid, ultracentrifuged at 45,000 rpm at 4C for 60 min, and the
supernatant was collected as the ‘‘insoluble fraction.’’
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